Search results
Results from the WOW.Com Content Network
Higher platelet transfusion thresholds have been used in premature neonates, but this has been based on limited evidence. [19] There is now evidence that using a high platelet count threshold (50 x 10 9 /L) increases the risk of death or bleeding compared to a lower platelet count threshold (25 x 10 9 /L) in premature neonates. [20]
In addition, given the short life span of transfused platelets, transfusions are needed regularly, increasing the overall risk of death of the baby. If intrauterine platelet transfusions are performed, they are generally repeated weekly (platelet lifespan after transfusion is approximately 8 to 10 days).
Platelet transfusion is contraindicated in thrombotic thrombocytopenic purpura (TTP), as it fuels the coagulopathy. Platelet transfusion is generally ineffective, and thus contraindicated, for prophylaxis in immune thrombocytopenia (ITP), because the transfused platelets are immediately cleared; however, it is indicated to treat bleeding. [70]
In a typical set of rules, a platelet donor must weigh at least 50 kg (110 lb) and have a platelet count of at least 150 x 10 9 /L (150,000 platelets per mm³). [2] One unit has greater than 3×10 11 platelets. Therefore, it takes 2 liters of blood having a platelet count of 150,000/mm³ to produce one unit of platelets.
They form aggregates with white blood cells and in adults the platelets that are bound to white blood cells are usually activated. In children, these white blood cell-platelet aggregates are increased in children compared to adult levels, however this takes place without a corresponding increase in platelet activation. [ 10 ]
The first blood transfusion from animal to human was administered by Dr. Jean-Baptiste Denys, eminent physician to King Louis XIV of France, on June 15, 1667. [82] He transfused the blood of a sheep into a 15-year-old boy, who survived the transfusion. [83] Denys performed another transfusion into a labourer, who also survived.
Type I-CAMT is more severe and is characterized by low platelet counts and an early progression of bone marrow aplasia associated with pancytopenia. [1] The second type of Congenital amegakaryocytic thrombocytopenia is milder and presents with a transient increase of platelet counts during the first year of life.
Factor V is produced by megakaryocytes, which produce platelets and platelet-derived factor V, and hepatocytes, which produce plasma-derived factor V. [9] The molecule circulates in plasma as a single-chain molecule with a plasma half-life of 12–36 hours. [10] Factor V is able to bind to activated platelets and is activated by thrombin.